Clinical trial
Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune…
NCT00010387 · Johns Hopkins University, Other · Completed
Key facts
| NCT number | NCT00010387 |
|---|---|
| Title | Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease |
| Lead sponsor | Johns Hopkins University, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Anemia, Hemolytic, Autoimmune, Felty Syndrome, Purpura, Thrombocytopenic, Autoimmune Diseases |
| Intervention type | Drug |
| Interventions | cyclophosphamide, filgrastim |
| Enrollment | 32 |
| Start date | Mar 1, 1999 |
| Primary completion | Aug 1, 2007 |
| First posted | Feb 2, 2001 |
| Last update posted | Sep 10, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: